Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B
Antivirale behandeling van chronische hepatitis B: het optimaliseren van behandelstrategieën met nucleos(t)ideanalogen
Hepatitis B infection has a complex natural history and causes a wide spectrum of disease. Although effective vaccines are available, universal vaccination has yet not been reached. Currently, an estimated 350 million people are chronically infected, and 0.5-1.2 million subjects die every year due to long-term sequalae of hepatitis B related chronic liver disease, such as liver cirrhosis and hepatocellular carcinoma Despite evidence-based treatment guidelines areas of disagreement on the management of chronic hepatitis B virus (HBV) infection still exist. With the currently approved treatment options the ultimate goal is to prevent the development of long-term sequelae of chronic liver disease. Current treatment strategies consist of either therapies with fi nite duration that aims to achieve sustained off-treatment remission (interferon-based therapy), or long-term therapy that aims to maintain on-treatment response (nucleos(t)ide analogues).
|Keywords||HIV, Hepatitis B, infectious diseases, liver diseases, virology|
|Promotor||H.L.A. Janssen (Harry)|
|Publisher||Erasmus University Rotterdam|
|Sponsor||Erasmus MC Rotterdam, Nederlandse Vereniging voor Gastroenterologie, Novartis, Gilead Sciences, Bristol-Myers Squibb, J.E. Jurriaanse Stichting|
Reijnders, J.G.P. (2010, November 24). Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B. Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/21420